To synthesize insights from recent studies on the interdependent regulatory network linking the tumor microenvironment (TME), metabolic reprogramming, and tumor progression.
Approach:
Key Findings:
The TME drives metabolic reprogramming and is influenced by tumor metabolites that suppress antitumor immunity.
Key roles of the TME and metabolic reprogramming in tumorigenesis and therapeutic resistance were highlighted.
Future research directions include lipid metabolism, noncoding RNAs, exosomes, and immunotherapy.
Interpretation:
The studies reveal complex interactions between the TME and metabolic processes, suggesting a need for integrated approaches in cancer therapy.
Conclusion:
Future cancer treatment will likely integrate multi-omics analysis, spatial biology technologies, and combined targeted metabolic-immune therapies.
